Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 306

1.

Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation.

McAdams D, Wollein Waldetoft K, Tedijanto C, Lipsitch M, Brown SP.

PLoS Biol. 2019 May 16;17(5):e3000250. doi: 10.1371/journal.pbio.3000250. eCollection 2019 May.

2.

On the evolutionary ecology of multidrug resistance in bacteria.

Lehtinen S, Blanquart F, Lipsitch M, Fraser C; with the Maela Pneumococcal Collaboration.

PLoS Pathog. 2019 May 13;15(5):e1007763. doi: 10.1371/journal.ppat.1007763. eCollection 2019 May.

3.

On the role of different age groups during pertussis epidemics in California, 2010 and 2014.

Mahmud AS, Lipsitch M, Goldstein E.

Epidemiol Infect. 2019 Jan;147:e184. doi: 10.1017/S0950268819000761.

4.

Response to comment on 'The distribution of antibiotic use and its association with antibiotic resistance'.

Olesen SW, Lipsitch M, Grad YH.

Elife. 2019 May 3;8. pii: e47124. doi: 10.7554/eLife.47124.

5.

Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa.

Abuelezam NN, McCormick AW, Surface ED, Fussell T, Freedberg KA, Lipsitch M, Seage GR.

Epidemiol Infect. 2019 Jan;147:e122. doi: 10.1017/S0950268818003497.

6.

Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis.

Hitchings MDT, Coldiron ME, Grais RF, Lipsitch M.

PLoS Negl Trop Dis. 2019 Mar 11;13(3):e0007077. doi: 10.1371/journal.pntd.0007077. eCollection 2019 Mar.

7.

Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states.

Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M.

Int J Antimicrob Agents. 2019 Jul;54(1):23-34. doi: 10.1016/j.ijantimicag.2019.03.004. Epub 2019 Mar 6.

PMID:
30851403
8.

Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage.

Yang A, Cai F, Lipsitch M.

BMC Infect Dis. 2019 Mar 5;19(1):227. doi: 10.1186/s12879-019-3833-6.

9.

Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose.

Langwig KE, Gomes MGM, Clark MD, Kwitny M, Yamada S, Wargo AR, Lipsitch M.

Sci Rep. 2019 Mar 1;9(1):3203. doi: 10.1038/s41598-019-39698-x.

10.

Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13.

Mitchell PK, Azarian T, Croucher NJ, Callendrello A, Thompson CM, Pelton SI, Lipsitch M, Hanage WP.

Microb Genom. 2019 Feb;5(2). doi: 10.1099/mgen.0.000252. Epub 2019 Feb 19.

11.

THE AUTHORS REPLY.

Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M.

Am J Epidemiol. 2019 Apr 1;188(4):807-808. doi: 10.1093/aje/kwz018. No abstract available.

PMID:
30689694
12.

Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination.

Campo JJ, Le TQ, Pablo JV, Hung C, Teng AA, Tettelin H, Tate A, Hanage WP, Alderson MR, Liang X, Malley R, Lipsitch M, Croucher NJ.

Elife. 2018 Dec 28;7. pii: e37015. doi: 10.7554/eLife.37015.

13.

The distribution of antibiotic use and its association with antibiotic resistance.

Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernández-Díaz S, Lipsitch M, Grad YH.

Elife. 2018 Dec 18;7. pii: e39435. doi: 10.7554/eLife.39435.

14.

Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.

Tedijanto C, Olesen SW, Grad YH, Lipsitch M.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11988-E11995. doi: 10.1073/pnas.1810840115.

15.

Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR.

Sevilla JP, Bloom DE, Cadarette D, Jit M, Lipsitch M.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12911-12919. doi: 10.1073/pnas.1717161115.

16.

Microbiome as a tool and a target in the effort to address antimicrobial resistance.

Relman DA, Lipsitch M.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12902-12910. doi: 10.1073/pnas.1717163115.

17.

Models of immune selection for multi-locus antigenic diversity of pathogens.

Georgieva M, Buckee CO, Lipsitch M.

Nat Rev Immunol. 2019 Jan;19(1):55-62. doi: 10.1038/s41577-018-0092-5. Review.

PMID:
30479379
18.

The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-Spectrum Beta-lactamase-Producing Escherichia coli.

MacFadden DR, Fisman DN, Hanage WP, Lipsitch M.

Clin Infect Dis. 2018 Nov 20. doi: 10.1093/cid/ciy978. [Epub ahead of print]

PMID:
30462185
19.

Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.

Kahn R, Hitchings M, Wang R, Bellan SE, Lipsitch M.

Am J Epidemiol. 2019 Feb 1;188(2):467-474. doi: 10.1093/aje/kwy239.

PMID:
30329134
20.

Use of an individual-based model of pneumococcal carriage for planning a randomized trial of a whole-cell vaccine.

Cai FY, Fussell T, Cobey S, Lipsitch M.

PLoS Comput Biol. 2018 Oct 1;14(10):e1006333. doi: 10.1371/journal.pcbi.1006333. eCollection 2018 Oct.

21.

Azithromycin Susceptibility Among Neisseria gonorrhoeae Isolates and Seasonal Macrolide Use.

Olesen SW, Torrone EA, Papp JR, Kirkcaldy RD, Lipsitch M, Grad YH.

J Infect Dis. 2019 Jan 29;219(4):619-623. doi: 10.1093/infdis/jiy551.

PMID:
30239814
22.

Challenges of vaccine effectiveness and waning studies.

Lipsitch M.

Clin Infect Dis. 2018 Sep 10. doi: 10.1093/cid/ciy773. [Epub ahead of print] No abstract available.

PMID:
30204853
23.

Why Do Exceptionally Dangerous Gain-of-Function Experiments in Influenza?

Lipsitch M.

Methods Mol Biol. 2018;1836:589-608. doi: 10.1007/978-1-4939-8678-1_29. Review.

PMID:
30151594
24.

Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M.

Am J Epidemiol. 2018 Dec 1;187(12):2686-2697. doi: 10.1093/aje/kwy163.

PMID:
30099505
25.

Opinion: Risk to study nonparticipants: A procedural approach.

Eyal N, Lipsitch M, Bärnighausen T, Wikler D.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):8051-8053. doi: 10.1073/pnas.1810920115. No abstract available.

26.

Choices in vaccine trial design in epidemics of emerging infections.

Kahn R, Rid A, Smith PG, Eyal N, Lipsitch M.

PLoS Med. 2018 Aug 7;15(8):e1002632. doi: 10.1371/journal.pmed.1002632. eCollection 2018 Aug.

27.

Can antibiotic resistance be reduced by vaccinating against respiratory disease?

Atkins KE, Lipsitch M.

Lancet Respir Med. 2018 Nov;6(11):820-821. doi: 10.1016/S2213-2600(18)30328-X. Epub 2018 Jul 31. No abstract available.

PMID:
30076121
28.

Trends in outpatient antibiotic use and prescribing practice among US older adults, 2011-15: observational study.

Olesen SW, Barnett ML, MacFadden DR, Lipsitch M, Grad YH.

BMJ. 2018 Jul 27;362:k3155. doi: 10.1136/bmj.k3155.

29.

On the Role of Different Age Groups and Pertussis Vaccines During the 2012 Outbreak in Wisconsin.

Goldstein E, Worby CJ, Lipsitch M.

Open Forum Infect Dis. 2018 Apr 16;5(5):ofy082. doi: 10.1093/ofid/ofy082. eCollection 2018 May.

30.

The evolution of antibiotic resistance in a structured host population.

Blanquart F, Lehtinen S, Lipsitch M, Fraser C.

J R Soc Interface. 2018 Jun;15(143). pii: 20180040. doi: 10.1098/rsif.2018.0040.

31.

Impact of Antimicrobial Treatment for Acute Otitis Media on Carriage Dynamics of Penicillin-Susceptible and Penicillin-Nonsusceptible Streptococcus pneumoniae.

Lewnard JA, Tähtinen PA, Laine MK, Lindholm L, Jalava J, Huovinen P, Lipsitch M, Ruohola A.

J Infect Dis. 2018 Sep 22;218(9):1356-1366. doi: 10.1093/infdis/jiy343.

PMID:
29873739
32.

Multidrug-resistant Neisseria gonorrhoeae: implications for future treatment strategies.

MacFadden DR, Lipsitch M, Olesen SW, Grad Y.

Lancet Infect Dis. 2018 Jun;18(6):599. doi: 10.1016/S1473-3099(18)30274-3. No abstract available.

PMID:
29856349
33.

The impact of serotype-specific vaccination on phylodynamic parameters of Streptococcus pneumoniae and the pneumococcal pan-genome.

Azarian T, Grant LR, Arnold BJ, Hammitt LL, Reid R, Santosham M, Weatherholtz R, Goklish N, Thompson CM, Bentley SD, O'Brien KL, Hanage WP, Lipsitch M.

PLoS Pathog. 2018 Apr 4;14(4):e1006966. doi: 10.1371/journal.ppat.1006966. eCollection 2018 Apr.

34.

Preprints: An underutilized mechanism to accelerate outbreak science.

Johansson MA, Reich NG, Meyers LA, Lipsitch M.

PLoS Med. 2018 Apr 3;15(4):e1002549. doi: 10.1371/journal.pmed.1002549. eCollection 2018 Apr.

35.

Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.

Georgieva M, Kagedan L, Lu YJ, Thompson CM, Lipsitch M.

MBio. 2018 Mar 13;9(2). pii: e00264-18. doi: 10.1128/mBio.00264-18.

36.

Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.

Hitchings MDT, Lipsitch M, Wang R, Bellan SE.

Am J Epidemiol. 2018 Aug 1;187(8):1763-1771. doi: 10.1093/aje/kwy047.

PMID:
29522080
37.

Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.

Kahn R, Hitchings M, Bellan S, Lipsitch M.

Clin Trials. 2018 Apr;15(2):207-211. doi: 10.1177/1740774517752671. Epub 2018 Jan 27.

38.

Weak Epistasis May Drive Adaptation in Recombining Bacteria.

Arnold BJ, Gutmann MU, Grad YH, Sheppard SK, Corander J, Lipsitch M, Hanage WP.

Genetics. 2018 Mar;208(3):1247-1260. doi: 10.1534/genetics.117.300662. Epub 2018 Jan 12.

39.

Simulations for designing and interpreting intervention trials in infectious diseases.

Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M.

BMC Med. 2017 Dec 29;15(1):223. doi: 10.1186/s12916-017-0985-3.

40.

Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.

Lipsitch M, Li LM, Patterson S, Trammel J, Juergens C, Gruber WC, Scott DA, Dagan R.

Vaccine. 2018 Jan 25;36(4):473-478. doi: 10.1016/j.vaccine.2017.12.015. Epub 2017 Dec 14.

41.

Vaccine Effects on Heterogeneity in Susceptibility and Implications for Population Health Management.

Langwig KE, Wargo AR, Jones DR, Viss JR, Rutan BJ, Egan NA, Sá-Guimarães P, Kim MS, Kurath G, Gomes MGM, Lipsitch M.

MBio. 2017 Nov 21;8(6). pii: e00796-17. doi: 10.1128/mBio.00796-17.

42.

Shared Genomic Variants: Identification of Transmission Routes Using Pathogen Deep-Sequence Data.

Worby CJ, Lipsitch M, Hanage WP.

Am J Epidemiol. 2017 Nov 15;186(10):1209-1216. doi: 10.1093/aje/kwx182.

43.

On the Relative Role of Different Age Groups During Epidemics Associated With Respiratory Syncytial Virus.

Goldstein E, Nguyen HH, Liu P, Viboud C, Steiner CA, Worby CJ, Lipsitch M.

J Infect Dis. 2018 Jan 4;217(2):238-244. doi: 10.1093/infdis/jix575.

44.

Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination.

Masala GL, Lipsitch M, Bottomley C, Flasche S.

J R Soc Interface. 2017 Nov;14(136). pii: 20170620. doi: 10.1098/rsif.2017.0620.

45.

Frequency-dependent selection in vaccine-associated pneumococcal population dynamics.

Corander J, Fraser C, Gutmann MU, Arnold B, Hanage WP, Bentley SD, Lipsitch M, Croucher NJ.

Nat Ecol Evol. 2017 Dec;1(12):1950-1960. doi: 10.1038/s41559-017-0337-x. Epub 2017 Oct 16.

46.

Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines.

Lewnard JA, Givon-Lavi N, Weinberger DM, Lipsitch M, Dagan R.

Clin Infect Dis. 2017 Nov 13;65(11):1853-1861. doi: 10.1093/cid/cix673.

47.

Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period.

Lee GM, Kleinman K, Pelton S, Lipsitch M, Huang SS, Lakoma M, Dutta-Linn M, Rett M, Hanage WP, Finkelstein JA.

Pediatrics. 2017 Nov;140(5). pii: e20170001. doi: 10.1542/peds.2017-0001. Epub 2017 Oct 4.

48.

Host population structure and treatment frequency maintain balancing selection on drug resistance.

Cobey S, Baskerville EB, Colijn C, Hanage W, Fraser C, Lipsitch M.

J R Soc Interface. 2017 Aug;14(133). pii: 20170295. doi: 10.1098/rsif.2017.0295.

49.

If a Global Catastrophic Biological Risk Materializes, at What Stage Will We Recognize It?

Lipsitch M.

Health Secur. 2017 Jul/Aug;15(4):331-334. doi: 10.1089/hs.2017.0037. Epub 2017 Jul 26. No abstract available.

50.

Improving vaccine trials in infectious disease emergencies.

Lipsitch M, Eyal N.

Science. 2017 Jul 14;357(6347):153-156. doi: 10.1126/science.aam8334. Review.

Supplemental Content

Loading ...
Support Center